Seres Therapeutics Inc. (Nasdaq: MCRB)

https://www.serestherapeutics.com

LinkedIn: https://linkedin.com/company/seres-tx

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and plans to initiate a clinical program with SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. *

	Start	2016-01-11 existent
	Predecessor	Seres Health Inc.
	Industry	microbiomics
	Industry 2	SER-109 (Seres Therapeutics)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	200 Sidney Street
	City	02139 Cambridge, MA
	Tel	+1-617-945-9626
		Address record changed: 2024-01-05

Basic data	Employees	D: 101 to 500 (2024-01-01)
	Currency	USD
	Annual sales	126,325,000 (revenue, total, consolidated (2023) 2023-12-31)
	Profit	-113,724,000 (2023-12-31)
	Cash	127,965,000 (2023-12-31)

		* Document for »About Section«: Seres Therapeutics, Inc.. (5/20/21). "Press Release: Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development". Cambridge, MA.

		Record changed: 2024-08-12

Picture Informa Connect BioProcess Intl Europe 2025 Hamburg Agenda 650x100px

More documents for Seres Therapeutics Inc. (Nasdaq: MCRB)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)